Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
In the register
The register attaches this trial to Deuruxolitinib (Leqselvi) (Sun Pharmaceutical), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Concert Pharmaceuticals
- Participants (registry)
- 517
- Start
- June 2021
- Primary completion
- June 2022
- Study completion
- June 2022
- Last registry update
- July 2023
- Countries
- United States, Canada, France, Germany, Hungary, Poland, Spain
Conditions studied: Alopecia Areata
Interventions: CTP-543 matching placebo, CTP-543
Other trials of Deuruxolitinib (Leqselvi)
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.